Fed. Circ. Questions If Safer OxyContin Profits Came From IP

By Dani Kass · October 7, 2024, 9:39 PM EDT

An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

Purdue Pharma L.P. v. Accord Healthcare, Inc.

Case Number

23-1953

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

May 30, 2023

Featured Stories

Incora Uptier Fight Lays Bare Risks For Private Equity Backers No Photo Available

Alex Wittenberg

In the bruising battles for position among lenders to debt-laden companies, private equity firms often remain relatively unscathed. Bu... (more story)

The Onion's Infowars Bid Rests On Whether Highest Is Best No Photo Available

Ben Zigterman

As satirical media company The Onion prepares to defend its offer to buy Alex Jones' right-wing conspiracy show, Infowars, it is relyi... (more story)

How Spirit Airlines Landed In Bankruptcy Court No Photo Available

Emlyn Cameron

Ultra-low-cost airline Spirit has always been more susceptible to inflationary pressures than its costlier competitors, but its failed... (more story)